Growing collaborative of leading biobanks offers biomedical researchers unprecedented access to clinical-grade biomaterial.
Beltsville, MD, and Portland, ME, October 19, 2010 – BioServe and the Maine Medical Center (MMC) today announced that MMC’s Tissue Bank is joining the BioServe Network, which is fast becoming the richest resource of high-quality biomaterial in the world. Members of The BioServe Network today include Fox Chase Cancer Center, The Fairbanks Institute for Health Communities, the University of Massachusetts Medical School, Windber Research Institute, and now the MMC Tissue Bank. By accessing this 1.5 million and growing sample biorepository network, researchers can obtain the highest quality biomaterial from most any major disease category.
Founded in 2003 by Dr. Michael Jones, the Chair of the Department of Pathology at Maine Medical Center, the goal of the Maine Medical Center Tissue Bank is to accelerate the discovery of new and improved medical tests and treatments for patients by providing researchers access to specific tissue samples.
“Banking tissue is critical to advancing knowledge in the discipline of molecular genetics. This improves researchers’ understanding of human disease, leading to better screening for early diagnosis and, ultimately, to the discovery and development of new treatments,” said Dr. Paul Auclair, Medical Director of the MMC Tissue Bank. “By joining the BioServe Network we are able to get our high-quality and data-rich samples into the hands of many more scientists at institutions around the world.”
“We welcome the MCC Tissue Bank to the BioServe Network,” said Rama Modali, President of BioServe. “Whether validating a biomarker or a pre-clinical study of an experimental drug compound, human tissue is proving to be a significant accelerator of research. By accessing The BioServe Network we ensure that scientists are able to get the highest quality biosamples they need in their research.”
All biosamples in the Network are acquired using rigorous IRB-approved collection protocols, complete with HIPAA-compliant informed consent parameters. This makes each sample eligible for study in a commercial research setting. The BioServe Network provides full disclosure on where and how samples were sourced, and that all biosamples are collected using the highest standard SOPs.